INS and Hepatic steatosis: SCFAs can reduce the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ), leading to the increased oxidative metabolism of the liver and adipose tissue, reduced body fat accumulation, and hepatic steatosis, as well as increased insulin sensitivity.